Journal of addiction medicine · 2025
Treating Hepatitis C Within Real-world Telemedicine Addiction Care.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lira Marlene C, Hendy Lauren E, Tsui Judith I, Page Kimberly, Jimes Cynthia, Barrett Eileen, Brigham Shannon, Coffey Michael Justin
Аннотация
OBJECTIVES: Individuals receiving treatment for opioid use disorder (OUD) represent a key population for hepatitis C diagnosis and treatment. Integrating hepatitis C treatment within telemedicine addiction care offers a new opportunity to reach this population.
METHODS: We conducted a chart review of individuals prescribed hepatitis C treatment within a telemedicine treatment program for OUD. Patient medical records were reviewed to extract details on demographics, hepatitis C history, medication prior authorization, initiation and completion, and viral clearance testing.
RESULTS: Sixty-three treatment-naïve patients were prescribed antiviral therapy for hepatitis C by their addiction treatment medical providers with a median age of 36, 41% of patients identifying as female, and 57% insured by Medicaid. Approximately 1 in 5 patients were denied prior authorization for antiviral therapy. Among 63 patients initially prescribed medication, 33 (52%) completed treatment.
CONCLUSIONS: Telehealth programs for addiction are a feasible platform for expanding hepatitis C treatment to patients with OUD. Policies to reduce restrictions on antiviral coverage by payers could increase medication access through telehealth.
METHODS: We conducted a chart review of individuals prescribed hepatitis C treatment within a telemedicine treatment program for OUD. Patient medical records were reviewed to extract details on demographics, hepatitis C history, medication prior authorization, initiation and completion, and viral clearance testing.
RESULTS: Sixty-three treatment-naïve patients were prescribed antiviral therapy for hepatitis C by their addiction treatment medical providers with a median age of 36, 41% of patients identifying as female, and 57% insured by Medicaid. Approximately 1 in 5 patients were denied prior authorization for antiviral therapy. Among 63 patients initially prescribed medication, 33 (52%) completed treatment.
CONCLUSIONS: Telehealth programs for addiction are a feasible platform for expanding hepatitis C treatment to patients with OUD. Policies to reduce restrictions on antiviral coverage by payers could increase medication access through telehealth.